Adaptive Biotechnologies Corp vs LyondellBasell Industries NV — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while LyondellBasell Industries NV trades at $63.7 (market cap $20.67B). The key difference: LyondellBasell Industries NV is far larger — about 5.1× Adaptive Biotechnologies Corp's market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LYB | |
|---|---|---|
Market Cap | $4.04B | $20.67B |
Sector | Health | Basic Materials |
52-Week High | $25.45 | $82.38 |
52-Week Low | $12.30 | $42.28 |
Enterprise Value | $4.10B | $32.26B |
Dividend Yield | — | 6.44% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →